Select: All | None

Select: All | None

Select: All | None

Featured Opportunity

Novel Cell Isolation Method for Bio-engineering Artificial Cartilage

University of Alberta

-

PEPTIDOMIMETICS COMPRISING N-AMINO CYCLIC UREA RESIDUES AND USES THEREOF

HOPITAL MAISONNEUVE-ROSEMONT, University of Montreal

Novel peptidomimetics comprising N-amino cyclic urea residues are disclosed. Use of such peptidomimetics for modulating the activity of CD36 or IL-1 receptor in a cell, and for treating CD36- or IL-1-related disease, disorder or condition, is also described.

MODULATORS OF LIPOXYGENASE AND CYCLOOXYGENASE ENZYME ACTIVITY

Université de Moncton

The present invention relates to modulators of lipoxygenase and/or cyclooxygenase enzyme. The present invention also provides compositions comprising such modulators, and methods therewith for treating lipoxygenase receptor mediated diseases.

EXTRACELLULAR MITOCHONDRIAL COMPONENTS FOR DETECTING INFLAMMATORY REACTIONS AND CONDITIONS

Hema-Quebec, HÉMA-QUÉBEC, Laval University, University of Washington

The present disclosure highlights the relationship between extracellular mitochondrial components, optionally in combination with the secreted phospholipase A2-IIA and/or an auto-antibody, and in vivo as well as in vitro and inflammatory reactions/conditions, especially those released as a result of the degradation of a platelet. The present disclosure provides methods for determining the presence of inflammatory mediators, for limiting inflammatory reactions/conditions, for the diagnosis...

METHODS OF TREATING AUTOIMMUNE DISEASE

University of Calgary

Described herein are compositions and methods useful for treating autoimmune diseases and inflammatory disorders. The compositions and methods utilize ubiquitous, non-tissue specific antigens associated with major histocompatibility complexes (MHCs) and coupled to a nanoparticle core to induce regulatory T cells and regulatory B cells.

PROTEIN C RS2069915 AS A RESPONSE PREDICTOR TO SURVIVAL AND ADMINISTRATION OF ACTIVATED PROTEIN C OR PROTEIN C-LIKE COMPOUND

ELI LILLY AND COMPANY, SIRIUS GENOMICS, University of British Columbia

Provided herein are methods, oligonucleotides and peptide nucleic acids, compositions and kits for predicting a subject's response to treatment with activated protein C or protein C-like compound or susceptibility to major organ dysfunction or susceptibility to an inflammatory condition. The method generally comprises determining a genotype of said subject at one or more of polymorphic sites in the subject's protein C gene selected from one or more of the following: rs20069915 and one or...

MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE 14 (MAP3K14) POLYMORPHISMS AS INDICATORS OF SUBJECT OUTCOME IN CRITICALLY 111 SUBJECTS

SIRIUS GENOMICS, University of British Columbia

The present application provides methods, uses, commercial packages, and kits for obtaining a prognosis for a subject having or at risk of developing an inflammatory condition and for identifying subjects having a greater benefit from treatment with an anti-inflammatory agent or an anti-coagulant agent. The method generally includes determining the genotype at position rs7222094 or a polymorphic site in linkage disequilibrium thereto for a subject for a polymorphisms in the these genes. The...

PLASMINOGEN ACTIVATOR INHIBITOR-1 (PAI-1) HAPLOTYPES USEFUL AS INDICATORS OF PATIENT OUTCOME

University of British Columbia

The invention provides methods and kits for obtaining a prognosis for a patient having or at risk of developing an inflammatory condition. The metho d generally comprises determining a Plasminogen Activator Inhibitor-1 (PAI-1) genotype of a patient for one or more polymorphisms in the PAI-1 gene of the patient, comparing the determined genotype with known genotypes for the polymorphism that correspond with the ability of the patient to recover from the inflammatory condition and identifying...

NOVEL RECEPTOR FOR CD40L AND USES THEREOF

CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL

The present invention relates to a novel CD40L receptor and its related activities. Methods, uses, reagents and kits for the modulation of CD40L activities related to its interaction with the novel receptor are disclosed. Also disclosed are therapeutic uses of reagents in treating CD40L-related disorders.

DISSOLVED PROTEIN ARTHRITIS MARKERS

University of British Columbia

Methods and kits for diagnosing arthritis are provided. The methods may involve detection of 14-3-3 eta or gamma proteins in a sera or synovial fluid sample.

To help us serve you better,

please tell us what sector you work in: